Ryan Drexler - Musclepharm Corp Executive Chairman
| MSLPDelisted Stock | USD 0 0.0002 15.38% |
Chairman
Mr. Ryan Charles Drexler is Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Drexler was appointed to serve as our Chief Executive Officer and President on November 18, 2016. Prior to that, Mr. Drexler served as our Interim Chief Executive Officer, President and Chairman of the Board of Directors since March 15, 2016. Mr. Drexler has served as Chairman of our Board of Directors since August 26, 2015. Mr. Drexler is currently the Chief Executive Officer of Consac, LLC, a privatelyheld firm that invests in the securities of publiclytraded and venturestage companies. Previously, Mr. Drexler served as President of Country Life Vitamins, a familyowned nutritional supplements and natural products company that he joined in 1993. In addition to developing strategic objectives and overseeing acquisitions for Country Life, Mr. Drexler created new brands that include the BioChem family of sports and fitness nutrition products. Mr. Drexler negotiated and led the process which resulted in the sale of Country Life in 2007 to the Japanese conglomerate Kikkoman Corp since 2017.
| Age | 52 |
| Tenure | 7 years |
| Phone | 800 859 3010 |
| Web | https://www.musclepharm.com |
Musclepharm Corp Management Efficiency
The company has return on total asset (ROA) of (0.665) % which means that it has lost $0.665 on every $100 spent on assets. This is way below average. Musclepharm Corp's management efficiency ratios could be used to measure how well Musclepharm Corp manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.64 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. Musclepharm Corp has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Musclepharm Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Musclepharm Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Musclepharm Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Musclepharm to invest in growth at high rates of return. When we think about Musclepharm Corp's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Daniel DeLawder | Park National | 68 | |
| LDavid Trautman | Park National | 60 | |
| Mark Hogan | BCB Bancorp | 48 | |
| Hidetoshi Sakuma | Chiba Bank Ltd | 71 | |
| Zhongrong Yuan | Guangzhou Automobile Group | 57 | |
| Francis Scricco | Visteon Corp | 69 | |
| Fangyou Zhang | Guangzhou Automobile Group | 58 | |
| Joseph Brogan | BCB Bancorp | 75 | |
| Qinghong Zeng | Guangzhou Automobile Group | 62 | |
| Douglas Polinsky | Mill City Ventures | 65 | |
Management Performance
| Return On Asset | -0.66 |
Musclepharm Corp Leadership Team
Elected by the shareholders, the Musclepharm Corp's board of directors comprises two types of representatives: Musclepharm Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Musclepharm. The board's role is to monitor Musclepharm Corp's management team and ensure that shareholders' interests are well served. Musclepharm Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Musclepharm Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Lynch, CFO, Principal Financial Officer, Principal Accounting Officer | ||
| Gary Shirshac, Interim Officer | ||
| William Bush, Director | ||
| Moore DSc, Chief Board | ||
| Stacey Jenkins, Director | ||
| Noel Thompson, Independent Director | ||
| Michael Doron, Independent Director | ||
| Brad Pyatt, Chairman of the Board, CEO | ||
| Matthew Kerbel, Chief Marketing Officer | ||
| Alberto Andrade, COO | ||
| Brian Cavanaugh, Senior Vice President - Retail and Brand Strategy | ||
| Brian Casutto, Executive Vice President - Sales and Operations, Director | ||
| John Price, CFO | ||
| Ryan Drexler, Executive Chairman | ||
| Mark Groussman, Consultant | ||
| Douglas West, Interim Principal Financial Officer, Interim Principal Accounting Officer | ||
| John Mills, Sr. Managing Director | ||
| John Desmond, Independent Director | ||
| Eric Chin, Chief Director |
Musclepharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Musclepharm Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.66 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.23) % | |||
| Current Valuation | 22.12 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 53.50 % | |||
| Shares Owned By Institutions | 15.05 % | |||
| Price To Sales | 0 X | |||
| Revenue | 50.04 M | |||
| Gross Profit | 5.37 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Musclepharm Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Musclepharm Corp's short interest history, or implied volatility extrapolated from Musclepharm Corp options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Musclepharm Pink Sheet
If you are still planning to invest in Musclepharm Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Musclepharm Corp's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |